The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against...

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Parkinson's disease (PD) involves alpha-synuclein (aSyn) accumulation in dopaminergic neurons.
• The autophagy-lysosome pathway (ALP) is implicated in aSyn pathology.
• LRRK2 mutations are a significant cause of PD, affecting aSyn.
• RIT2 is a newly identified PD risk factor.

Purpose of the Study:

• To investigate the role of RIT2 in Parkinson's disease pathogenesis.
• To determine if RIT2 modulates LRRK2 activity and ALP function.
• To assess the therapeutic potential of RIT2 in PD models.

Main Methods:

• In vitro and in vivo studies using cell models and viral vectors.
• Analysis of RIT2 expression, ALP activity, and aSyn aggregation.
• Assessment of LRRK2 kinase activity and neuroprotection.

Main Results:

• RIT2 was selectively downregulated in PD models.
• RIT2 overexpression rescued ALP defects and reduced aSyn inclusions in G2019S-LRRK2 cells.
• RIT2 overexpression provided neuroprotection against aSyn toxicity in vivo.
• RIT2 inhibited A53T-aSyn-induced LRRK2 hyperactivation.
• RIT2 reduction mimicked LRRK2 mutation-induced ALP dysfunction.

Conclusions:

• RIT2 is essential for proper lysosome function and PD pathology.
• RIT2 acts as a negative regulator of LRRK2 kinase activity.
• RIT2 ameliorates ALP impairment and counteracts aSyn aggregation.
• Targeting RIT2 represents a potential therapeutic strategy for PD.